Single-domain antibody directed against human von Willebrand Factor (VWF)
Target:
Von Willebrand Factor
Target description:
Von Willebrand Factor (VWF) is a multimeric adhesive plasma glycoprotein that is important in the maintenance of hemostasis. It promotes adhesion of platelets to the sites of vessel injury by forming a bridge between subendothelial collagen and the platelet GPIb-IX-V receptor complex. VWF also acts as a chaperone for coagulation factor VIII, by delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma. Defects in VWF cause von Willebrand disease (VWD), a common inherited bleeding disorder characterized by excessive mucocutaneous bleeding. Type I VWD is the most common form and is characterized by a partial quantitative deficiency of a structurally and functionally normal VWF; type II VWD is caused by a qualitative deficiency and functional abnormalities of VWF; type III VWD is the most severe form and is associated with a total or near-total absence of VWF in plasma and cells, which also causes the profound deficiency of coagulation factor VIII in plasma.
Source:
Immunization with and phage-display selection on purified recombinant human VWF. Recombinant monoclonal single-domain antibody (Lama glama), purified from HEK293-E 253 cells using Nickel excel Sepharose affinity chromatography.
Product details.
Specificity:
Human VWF. Q118 recognizes human VWF in solution.
Formulation:
Myc-His tagged single-domain antibody in PBS.
Mol. Weight:
14.9 kDa
Ext. Coeff. (ε):
26373 M-1cm-1
A280 at 1g/L:
1.8
Storage:
Shipped on blue ice. Store at 4˚C or -20˚C (aliquots). Addition of 0.02% sodium azide is optional.